Skip to main content
Laekna, Inc. logo

Laekna, Inc. — Investor Relations & Filings

Ticker · 2105 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 130 across all filing types
Latest filing 2025-12-12 Governance Information
Country HK Hong Kong
Listing HKEX 2105

About Laekna, Inc.

http://www.laekna.com

Laekna, Inc. is a science-driven, clinical-stage biotechnology company founded in 2016. The company specializes in the discovery, development, and commercialization of innovative therapies, particularly focusing on immunology treatments. Laekna's core mission is to bring novel therapeutics to patients suffering from cancer (oncology), metabolic diseases, and liver fibrosis, addressing significant unmet medical needs across these therapeutic areas.

Recent filings

Filing Released Lang Actions
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Governance Information Classification · 1% confidence The document is titled 'LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS' and provides a breakdown of the board members, their executive/non-executive status, and their committee memberships. This type of disclosure is a standard corporate governance filing that details the composition of the board and its committees, which falls under the category of Governance Information.
2025-12-12 English
CHANGE OF THE COMPOSITION OF THE NOMINATION AND CORPORATE GOVERNANCE COMMITTEE
Board/Management Information Classification · 1% confidence The document is an official announcement from Laekna, Inc. regarding a change in the composition of its Nomination and Corporate Governance Committee. This involves the appointment of new members to a board committee. According to the provided definitions, announcements regarding changes in the company's board of directors or senior management (including committee appointments) fall under the 'MANG' category.
2025-12-12 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2025
Regulatory Filings Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in securities, share capital, and treasury shares. It does not fit into specific categories like 'Annual Report' or 'Earnings Release' but is a mandatory regulatory disclosure regarding capital structure changes. Therefore, it is classified as a Regulatory Filing (RNS).
2025-12-03 English
INSIDE INFORMATION EXCLUSIVE LICENSE AGREEMENT WITH QILU PHARMA FOR LAE002 (AFURESERTIB) IN THE CHINA REGION
M&A Activity Classification · 1% confidence The document is an announcement regarding an exclusive license agreement between Laekna, Inc. and Qilu Pharma for the drug LAE002. This constitutes a strategic business partnership and licensing deal, which falls under M&A Activity (TAR) as it involves the commercialization rights and licensing of a key asset.
2025-11-12 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2025
Regulatory Filings Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in securities, share capital, and treasury shares. As it is a recurring regulatory filing mandated by the Exchange Listing Rules and does not fit into specific categories like earnings releases or annual reports, it is classified as a Regulatory Filing (RNS).
2025-11-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2025
Share Issue/Capital Change Classification · 1% confidence The document is a mandatory monthly return under Hong Kong Listing Rule Chapter 19B detailing movements in share capital (authorised shares, issued shares, treasury shares), share option exercises, share award schemes, and a placing of new shares. It is not a financial report (IR/10-K) or AGM material; it specifically reports share issue and capital changes. Therefore it fits the “Share Issue/Capital Change” category (SHA).
2025-10-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.